Introduction
============

Substantial research demonstrated that regular physical activity (PA) exerts beneficial effects on cognitive performance in the elderly ([@B33]; [@B21]; [@B46]). More specifically, it has been shown that PA exerts a larger positive influence on tasks mainly tapping executive functions than other tasks focusing on speed of information processing or visuospatial processing ([@B12]). Different authors suggested that executive functions are not a unitary function but rather an umbrella of inter-correlated functions such as controlled inhibition, cognitive flexibility and updating of working memory ([@B18]; [@B40]). Within this diversity of executive functions, controlled inhibition seems to benefit more selectively from PA than the other executive functions ([@B52]; [@B5]; [@B47]; [@B26]). Controlled inhibition is the capacity to suppress irrelevant information or prepotent responses, and it plays a core role in the executive functions construct ([@B40]). Deterioration in inhibitory processes may play a central role in age-related declines in several different cognitive functions ([@B29]). However, some recent meta-analyses failed to demonstrate consistent and reliable benefits of PA on executive functions ([@B3]; [@B31]), despite the apparent consensus of the positive effects of PA on cognitive functioning in elderly populations. Differences in study designs, training programs or the methodology used to analyze the principal outcomes primarily explain these inconsistent results ([@B4]). Another way explaining these discrepancies is the variety of participant characteristics in these studies, such as gender and age (see [@B23]), or education level. The genetic profile is also an important factor that influences cognition, but it has received very little attention.

Several brain molecular and cellular mechanisms, such as the synthesis of neurotrophic proteins, progressively change during the aging process ([@B28]). Brain-derived neurotrophic factor (BDNF) is one of the main proteins involved in cerebral functioning ([@B42]; [@B1]; [@B53]), and its secretion decreases during aging ([@B44]). BDNF release is associated with the genetic profile of its gene. In other respect, regular PA was also associated with higher concentration of BDNF in the brain and enhancement of brain plasticity ([@B13]; [@B14]).

A single nucleotide polymorphism in the *BDNF* gene, *BDNFVal66Met*, affects BDNF secretion, and it may be involved in the deleterious effect of brain aging ([@B39]). The *Met* allele of the *BDNFVal66Met* polymorphism is present on one or two gene copies in 30% of the United States population ([@B51]). The deleterious effect of this *Met* allele reduces BDNF secretion in response to neuronal stimulation in adults ([@B19]; [@B34]). When brain BDNF levels decrease, a lower cognitive performance can thus be expected. As mentioned just earlier, a lower level of brain BDNF can be observed in sedentary people by comparison to active people ([@B56]; [@B17]) and/or in people with two Met alleles at codon 66 of the BDNF gene. The examination of a possible interaction between PA and BDNF polymorphism on different cognitive functions declining with aging, and more particularly executive functions, is then particularly important. For instance, it can be expected that the positive effect of PA on executive functions may counteract the negative effect of the BDNF polymorphism Met allele ([@B49]). In this perspective, several authors examined the interaction between *BDNF*Val66Met and PA in elderly participants on cognitive performance, brain volume and/or cerebral plasticity ([@B32]; [@B20]; [@B8]; [@B11]; [@B15]; [@B57]). Only the last study of [@B57] tested this interaction on executive functions. These authors demonstrated in a longitudinal study that *Val* carriers without PA exhibited poorer executive functions performance at age 75 than their peers with higher PA levels. In contrast, the level of PA did not affect executive functions performance in *Met-*heterozygous. It is interesting to note that they used four tasks tapping executive functions including two tasks well-known to involve controlled inhibition, the Stroop task and the Hayling sentence completion test. The results observed by [@B57] converge with those of a previous study conducted by our group ([@B11]), which demonstrated that only *Val-*homozygous older adults benefited from regular PA and exhibited better episodic memory performance compared to their *Val*-homozygous inactive counterparts. However, a same polymorphism can lead to notable variations in protein secretion in different ethnic groups (see [@B58]). Consequently, a replication of [@B57] data in a different population is important to generalize the results.

The present study used the same pool of participants aged 55 years and older than the study of [@B11] and examined the interaction between PA and the *BDNF* polymorphism on controlled inhibition performance using a modified Simon-like reaction time task. Participants in Simon-like tasks respond to a relevant stimulus feature (e.g., an arrow), and the position of the stimulus is always irrelevant ([@B59]). There is a dimensional overlap between the irrelevant stimulus feature, i.e., the position of the stimulus, and the response set, i.e., the direction of the arrow in the example. When the stimulus position corresponds with the response side (e.g., left key press to a stimulus that is presented on the left of the screen), the trial is considered congruent, and the responses are typically faster than incongruent trials, where there is a mismatch between the stimulus position and response side. The dual-route model (e.g., [@B35]) suggests that the relevant stimulus feature (e.g., the direction of the arrow) is processed via a controlled route and activates the correct response, and a second response code is activated by the position of the stimulus via an automatic route. [@B50] proposed that the automatic activation of the incorrect response is selectively suppressed by a central active inhibitory mechanism that requires time and may explain why participants respond slower on incongruent trials. The performance of older adults is consistently impaired in this type of task, but PA potentially reduces this impairment. It is also important to note that there is a problem of task impurity related to the measurement of the effectiveness and/or efficiency of a specific cognitive process ([@B10]; [@B45]). Generally, a cognitive task well-known to tap a cognitive process such as executive functions, or more specifically controlled inhibition, also involves other non-executive cognitive processes, for instance semantic memory. Consequently, a low performance observed in a specific task can be due to the executive component of the task and/or to the non-executive component of the task. The impurity of cognitive tasks may explain, on the one hand, the weak correlation between tasks well-known to tap executive functions ([@B41]) and, on the other hand, the weak reliability test--retest of these same tasks ([@B16]). It is recommended to use several tasks tapping the same cognitive function in the same study in order to avoid this problem of impurity. Another approach is to replicate the results using one or more tasks tapping the same cognitive process than the replicated study; this was the approach chosen in the present study.

The results of [@B11] and [@B57] suggest a PA × *BDNF* polymorphism interaction on cognitive performance such as the effect of PA on controlled inhibition will be significant only for the *Val-*homozygous carriers, and Met carriers will not be affected by PA. In this perspective, the present cross-sectional study aims to replicate the results obtained by [@B57] on controlled inhibition but using a different task tapping the controlled inhibition function in a sample of French participants.

Materials and Methods {#s1}
=====================

Study
-----

Data were collected within the "PRAUSE" survey conducted in Poitou-Charentes, France from 2011 to 2013 ([@B11]). A total of 466 retired volunteers aged 55 years and older (mean age = 75.72; *SD* = 9.84) were included in the survey. They have been contacted through a sampling frame of 3716 address records from the census surveys conducted by the French Institute of Statistics and Economical Studies (Institut national de la statistique et des études économiques -- INSEE). This master-sample for regional extensions was very representative of the senior population of Poitou-Charentes (France). The inclusion criteria of the study were: (1) to be 55 years old or more, (2) to live in Poitou-Charentes (France), (3) to be retired, in a situation of long-term unemployment, long-term sick leave or never engaged in the paid labor force. Non-native French speakers and people institutionalized in an Establishment of Accommodation for Dependent Old Persons (EHPAD) were excluded from participation. The survey was conducted at home and involved three sessions of 1.5--2 h each. A battery of cognitive tests and questionnaires was administered during these three sessions. Buccal swabs were taken during session 1 and the reaction time task was administered in session 3. There was an attrition rate of 39% between sessions 1 and 2, and 30% between sessions 2 and 3.

### Participants

A total of 114 participants (mean age = 71.53 years; *SD* = 9.13) of the 466 volunteers were included in the current analyses because they completed all required tests and questionnaires to test our hypothesis (see **Figure [1](#F1){ref-type="fig"}**). We selected only active participants with body mass index (BMI) less than 35 to increase the likelihood of observing a significant effect of PA on cognitive performance ([@B43]).

![Flow chart describing the selection process of participants. MMSE, mini mental state examination; *BDNF*Val66Met, brain-derived neurotrophic factor gene polymorphism; PA, level of physical activity.](fnhum-11-00541-g001){#F1}

This study was carried out in accordance with the recommendations of "Conseil National de l'Information Statistique" (CNIS) \[French National Council of Statistical Information\] and "Commission Nationale de l'Informatique et des Libertés" (CNIL) \[French National Commission on Informatics and Liberty\] with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by two national ethics committees: (1) the survey received the "general interest and statistical quality" label from the CNIS (Visa n°2012X907RG); and (2) authorization n°1593815 from the CNIS (deliberation n°2012-375).

Cognitive Assessments
---------------------

### Mini Mental State Examination

Global cognitive functioning was evaluated during the first session using the MMSE. Cognitive impairment (exclusion criterion) was defined as a score below 24 ([@B25]). Only participants with an MMSE score equal to or higher than 24 were included in the study.

### Controlled Inhibition

Inhibitory performance was assessed using a computerized reaction time task. The task was constructed and administered using E-Prime 2.0 software (Psychology Software Tools, Pittsburgh, PA, United States). The stimuli were arrows that appeared on the right or left of the computer screen. Participants responded as accurately and as rapidly as possible using a button press with a millisecond precision (Serial Response Box^TM^, Psychology software Tools, Pittsburgh, PA, United States) according to the direction indicated by the head of the arrow. If the arrow pointed to the right, the participant had to press the right key of the Serial Response Box with the right forefinger and if the arrow pointed to the left, he/she had to press the left key with the left forefinger (see **Figure [2](#F2){ref-type="fig"}**). On each trials, the following sequence of events occurred: a black fixation point appeared at the center of the screen for a mean duration of 500 ms, varying randomly between 300 and 700 ms with a 100 ms incremental step. The stimulus (arrow pointing to the left or right) appeared on the right or left side of the screen and remained until the onset of the participant's response (see **Figure [2](#F2){ref-type="fig"}**). Afterward, the screen went blank for 1000 ms following the onset of the participant' response or after a maximum of 2500 ms. There was a distance of approximatively 750 mm between the screen and the eyes of the participant. The stimulus (the arrow) was 20 mm wide and located at 137 mm from the center of the monitor. Measures of inhibition were obtained in one block of 300 trials, where 200 congruent trials and 100 incongruent trials were randomly presented. Congruent trials were trials where the arrow pointed to the right (→) and appeared on the right of the screen or pointed to the left (←) when appearing on the left of the screen. Incongruent trials were trials where the arrow pointed to the opposite side of its spatial location on the screen. We used mean reaction time (RT, in ms) data and error rate (in %) for incongruent and congruent trials as dependent variables. **Figure [2](#F2){ref-type="fig"}** described the experimental setup of the reaction time task.

![Setup of the reaction time task. **(A)** The direction of the arrow (toward the right side of the screen) is congruent with the location of the arrow (in the right side of the screen); the participant responds to the arrow by pressing the right key. **(B)** The direction of the arrow (toward the right side of the screen) in incongruent with the location of the arrow (in the left side of the screen); the participant responds to the arrow by pressing the right key. Congruent and incongruent stimuli had the same probability of occurrence in the right and the left side of the screen.](fnhum-11-00541-g002){#F2}

Genotyping
----------

DNA was extracted from buccal cells using a QIAamp DNA Blood Mini Kit (QIAGEN GmbH - QIAGEN Strasse 1. 40724 Hilden, Germany) according to the manufacturer's protocol. SNPs were genotyped using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) analysis. PCR amplification of the *BDNF* polymorphism *Val66Met* (rs6265) was performed using the forward primer 5′-GCCTACCCAGGTGTGCGG-3′ and the reverse fluorescent primer 5′-FAM-GAGGAGGCTCCAAAGGCAC-3′. PCR products were digested using the restriction enzyme Hsp92II (Promega Corporation -- 2800 Woods Hollow Road. Madison, WI 537 11-5399, United States) and resolved using capillary electrophoresis in an ABI PRISM 3130 DNA Genetic Analyzer (Applied Biosystem by Life Technologie, Thermo Fisher Scientific -- 168 Third Avenue, Waltham, MA, United States 02451).

The allelic frequency was estimated using Hardy Weinberg equilibrium and the khi^2^ test. The distribution of genotypes in the sample did not differ from the Hardy--Weinberg equilibrium (*p* = 0.65). Genetic data were analyzed using a dominance model that combined *Met* carriers into a single group (*Met/Met* + *Val/Met*) because the *Val/Met* and *Met/Met* genotypes were previously associated with decreased cognitive performance compared to *Val-*homozygous genotypes ([@B39]; [@B49]; [@B37]) and the low presence of the *Met/Met* genotype ([@B51]) in the population.

Physical Activity
-----------------

### The Historical Leisure Activity Questionnaire (HLAQ)

The level of current PA was evaluated during the second session using the HLAQ ([@B36]). This validated questionnaire was used to assess the history of PA weighted by their relative intensity. Participants were asked to report the frequency, type, intensity, and hours of PA performed during the present year. We used the Compendium of Physical Activities Tracking Guide 2011 ([@B2]) to obtain a specific metabolic equivalent (MET) for each PA. We calculated the average energy expenditure (Mets-h/week) for each participant using the HLAQ data and the compendium. We classified the participants according to their METs-h/week following World Health Organization (WHO) recommendations: participants with greater than or equal to 7.5 METs-h/week were in the active group and participants with lower than 7.5 METs-h/week were in the inactive group.

### The NASA/JSC Physical Activity Scale

All participants were asked to rate their current regular weekly physical practices during the first session to identify their PA level on a score from 0 to 7 using the NASA/JSC Physical Activity Scale ([@B30]). We used these data to confirm the participant's PA level in cases they were near the 7.5 METs-h/week (±0.50). Seventy-eight participants were evaluated using this verification method. They were considered active if their NASA/JSC PA score was strictly higher than 3. Participants who scored level 4 or above practiced regularly intensive PA at least 3 h per week (three participants). Participants were classified as inactive if their NASA/JSC PA score was strictly lower than 3 (one participant).

Group Constituents
------------------

We established four independent groups of participants according to their PA level (above or below 7.5 METs-h/week) and *BDNFVal66Met* profile (*Met* Carriers vs. *Val-*homozygous) (see **Table [1](#T1){ref-type="table"}**).

###### 

Demographic characteristics of participants.

  ------------------------------------------------------------------------------------------------------------------------
                            Active          Inactive        Total          Effects of\                    
                                                                           PA and BDNF                    
  ------------------------- --------------- --------------- -------------- -------------- --------------- ----------------
  Participants (n)          34              30              22             28             114             

  Age (years)               70,85 (8.48)    68.98 (8.95)    71.83 (9.19)   74.84 (9.47)   71.53 (9.13)    PA^∗^

  Gender (M/F)              22/13           15/15           11/11          8/20           56/58           PA^∗^, BDNF^∗^

  Visual acuity (N/W)       27/7            25/5            16/6           22/6           90/24           *NS*

  BMI (kg/m^2^)             26.01 (3.73)    27.23 (4.37)    28.94 (4.17)   28.92 (4.67)   27.57 (4.35)    PA^∗^

  MMSE (0--30)              28.06 (1.58)    28.40 (1.48)    28.59 (1.18)   27.71 (2.05)   28.17 (1.63)    *NS*

  Depression (0--30)        5.82 (4.85)     6.93 (5.40)     7.59 (5.40)    7.32 (4.39)    6.82 (4.98)     *NS*

  Education level (1--20)   10.09 (3.52)    11.60 (3.64)    11.18 (4.02)   10.14 (3.61)   10.71 (3.69)    *NS*

  Hour/week of PA           9.35 (5.59)     11.97 (8.76)    0.17 (0.42)    0.55 (0.70)    6.16 (7.48)     PA^∗^

  Mets-h/week of PA         48.53 (31.02)   62.20 (50.28)   0.61 (1.56)    2.24 (2.70)    31.78 (40.91)   PA^∗^
  ------------------------------------------------------------------------------------------------------------------------

Mean (± standard deviation); M, male; F, female; N, normal vision with or without correction; W, weakened vision even with correction; BMI, Body Mass Index; PA

∗

, significant main effect of PA; BDNF

∗

, significant main effect of BDNF polymorphism; NS, no effect of PA or BDNF.

Geriatric Depression Scale (GDS)
--------------------------------

The French version of the GDS ([@B6]) was used in order to assess the level of participants' depressive symptomatology (maximum = 30; [@B60]). Depression was evaluated because previous studies demonstrated an interaction between BDNF polymorphism and PA on depression ([@B9]; [@B38]; [@B22]). [@B7] suggested that depression scores from 1 to 10 be considered normal, while depression score ≥ 11 are indicative of possible depression.

Education Level
---------------

Education level contributes to cognitive reserves ([@B24]; [@B55]), and it strongly influences cognitive performance in older adults. Education level was evaluated as the number of years of formal education from the 1st year of elementary school (level 1) to the 3rd year of a Ph.D. degree (level 20) (1--20 years).

Statistical Analysis
--------------------

The assumption of data normality and homogeneity was assessed using Lilliefors and Levene tests, respectively. Error rates were not normally distributed, and these data were arcsine square-root transformed. We performed separate analyses of variance (ANOVAs) on mean RT and transformed error rates using a general linear model, with PA level (active vs. inactive) and *BDNF* polymorphism (*Met* carriers vs. *Val-*homozygous) as between-subjects factors and trial type (congruent vs. incongruent) as a within-subject factor. Analyses of covariance (ANCOVAs) were performed on the same measures, with gender, age and BMI as covariates because these factors were significantly associated with PA or *BDNF* polymorphism (see **Table [1](#T1){ref-type="table"}**). The level of significance was set at *p* \< 0.05, and partial estimated effect sizes ($\eta_{p}^{2}$) are reported for significant results. *Post hoc* mean comparisons were performed using Bonferroni corrections for multiple comparisons. All statistical and power analyses were conducted with Statistica 7.1 package ([@B54]).

Results
=======

The ANOVA on RT data revealed no main effect of PA \[*F*(1,110) = 2.23, *p* \> 0.13\] or *BDNF* polymorphism \[*F*(1,110) = 0.46, *p* \> 0.50\]. There was a significant effect of trial type. Congruent trials produced shorter RTs (*M* = 614.97 ms; *SD* = 11.60 ms) than incongruent trials (*M* = 770.26 ms; *SD* = 16.41 ms) \[*F*(1,110) = 314.45; *p* \< 0.05; $\eta_{p}^{2}$ = 0.77\]. The PA × *BDNF* polymorphism × trial type interaction was marginally significant \[*F*(1,110) = 3.184, *p* = 0.08\], which suggests that only *Val-*homozygous active participants exhibited shorter RT on incongruent trials compared to their *Val-*homozygous inactive counterparts. However, the results of the ANCOVA revealed that this interaction was not significant when controlling for age, gender and BMI \[*F*(1,102) = 1.88, *p* \> 0.18\]. A last ANCOVA on RT data with Visual acuity and Depression as additional covariates, pointed out no significant effect of Visual acuity \[*F*(1,100) = 0.30; *p* \> 0.58\] and a marginal effect of Depression \[*F*(1,100) = 3.51; *p* = 0.06\] on RT (**Table [2](#T2){ref-type="table"}**).

###### 

Mean RT (± standard deviation) for congruent and incongruent trials as a function of group of participants.

                          RT congruent trials   RT incongruent trials
  ----------------------- --------------------- -----------------------
  Active Met carriers     601.27 (104.10)       757.99 (172.32)
  Inactive Met carriers   610.82 (144.43)       756.48 (181.19)
  Active Val/Val          594.48 (109.76)       728.29 (155.03)
  Inactive Val/Val        649.04 (138.15)       828.59 (184.18)

Mean (± standard deviation); RT, reaction time (in ms).

The ANOVA on error rates revealed no main effect of PA \[*F*(1,110) = 2.90, *p* \> 0.09\] or *BDNF* polymorphism \[*F*(1,110) = 1.49, *p* \> 0.22\]. The effect of trial type was significant \[*F*(1,110) = 337.34; *p* \< 0.05; $\eta_{p}^{2}$ = 0.75\]. Participants made fewer errors for congruent trials (*M* = 1.24%; *SD* = 0.24%) than incongruent trials (*M* = 7.61%; *SD* = 0.60%). The PA × *BDNF* polymorphism × trial type interaction reached significance \[*F*(1,110) = 9.75, *p* \< 0.05, $\eta_{p}^{2}$ = 0.08\]. The results of the ANCOVA revealed that this interaction remained significant after controlling for age, gender and BMI \[*F*(1,102) = 6.72, *p* \< 0.05, $\eta_{p}^{2}$ = 0.06\]. The statistical power of this interaction was 72.8%. *Post hoc* analyses confirmed a significant difference in error rate between *Val/Val* active and *Val/Val* inactive participants only for the incongruent trials (*p* \< 0.01) and a significant difference between *Val/Val* inactive participants and *Met* carrier inactive participants only for the incongruent trials (*p* \< 0.01) (see **Figure [3](#F3){ref-type="fig"}**). A last ANCOVA on error rates with Visual acuity and Depression as additional covariates, pointed out no significant effect of Visual acuity \[*F*(1,100) = 0.25; *p* \> 0.61\] and a significant effect of Depression \[*F*(1,100) = 4.03; *p* \< 0.05; $\eta_{p}^{2}$ = 0.05\]. The interaction between PA × *BDNF* polymorphism × trial type remained significant despite controlling for these two additional covariates \[*F*(1,100) = 6.70; *p* \< 0.05; $\eta_{p}^{2}$ = 0.06\].

![Interaction between *BDNF* polymorphism (Met carriers vs. Val/Val) and Physical Activity (active vs. inactive) on average error rate (in %) in congruent and incongruent trials. Errors bars represent standard deviation. ^∗^*p* \< 0.01.](fnhum-11-00541-g003){#F3}

Discussion
==========

This study examined the interaction between PA and the *BDNFVal66Met* polymorphism on controlled inhibitory performance in older adults. Our hypothesis was that PA would interact with the *Val* allele on cognitive performance that involved conflict monitoring and controlled inhibition (i.e., the incongruent trials in our experimental task). The classical detrimental effect of no-dimensional overlap between the direction and location of the stimuli (i.e., an arrow) was clearly reproduced and demonstrated using RT and error rates. The dual-route model states that incongruent trials require more time to inhibit an automatic response, which leads to slower RT and a higher percentage of errors because of the failure of the inhibition process in some trials ([@B50]). However, we did not observe a clear significant interaction between PA and polymorphisms on the average RT for trials that involved controlled inhibition, but the interaction reached significance on error rates. Specifically, the interaction demonstrated that inactivity was associated with a significant increase in error rate only for inactive *Val-*homozygous participants in the incongruent condition. This interaction confirms that PA modulates the relationship between the BDNF polymorphism and controlled inhibition as measured using error rates for incongruent trials. More precisely, it suggests that PA and BDNF share a common neurophysiological mechanism that influences controlled inhibition. The most plausible mechanism that could play this role is the neurotrophic influence of BDNF on prefrontal neurons. Both exercise and the Val allele of the BDNF polymorphism increase the concentration of BDNF in the brain ([@B13]), consequently they must interact at a structural and/or a functional level in some regions of the brain, in this case prefrontal regions. Then, the interaction between PA and BDNF polymorphism observed in the present study gives a supplementary argument for the mediation role of BDNF in the causal link between exercise and cognition.

In addition, the present results confirm and extend the results obtained by [@B57]: inactive *Val-*homozygous exhibited a poorer performance in controlled inhibition than Met carriers and active Val homozygous. In the current study, the degraded performance corresponded to a higher error rate for incongruent trials in a Simon-like task. [@B57] observed very similar results using a Stroop task and a Hayling sentence completion task. These two studies strongly suggest that *Val-*homozygous individuals are more sensitive to PA level. Inactivity seems very deleterious for *Val-*homozygous carriers. Our results should be interpreted in light of the fact that physical inactivity is a new phenomenon from an evolutionary point of view. In contrast, the human genome is a product of a long evolutionary process that has remained stable for 10.000 years ([@B48]) and was built for hunters with periods of intense PA balanced with periods of rest. Therefore, the wild type *Val/Val* individuals could suffer more strongly from the effects of a sedentary lifestyle than Met carriers.

But why Met carriers did not demonstrate any positive effect of PA or negative effect of inactivity? The Met allele of the *BDNF* polymorphism is generally viewed as a deleterious variant because the *Met* allele reduces BDNF secretion in response to neuronal stimulation ([@B19]; [@B34]). It is important to note that this deleterious effect of the Met allele was not observed in the present experiment. However, it could be hypothesized that BDNF secretion level in *Met* carriers may not increase sufficiently in response to regular PA, and the BDNF rate would remain too low to benefit cognitive performance. Another mechanism may explain the similar performance of controlled inhibition in active and inactive *Met* carriers. Brown's hypothesis ([@B8]) is that the mature BDNF form is altered and inefficiently binds to the BDNF receptor (TrkB) in BDNF *Met* carriers, but the precursor form of BDNF (proBDNF) remains unaltered in BDNF *Met* carriers. Unfortunately, proBDNF binds its receptor (p75), and this link induces apoptosis. Therefore, Met carriers with high levels of PA may undergo higher levels of apoptotic changes in the brain because of the increasing proBDNF levels. Increasing mature BDNF levels in response to increased PA will not be sufficient to improve cognition. Notably, the Caucasian population exhibits an approximately 70% distribution of *Val*-homozygous ([@B51]). Val-homozygous carriers in our population exhibited the greatest benefit from the effects of PA, and 30% of the population (the Met carriers) was less or not sensitive to the effects of PA on controlled inhibition performance. Therefore, the cognitive improvements reported by epidemiological and interventional studies in primarily Western countries may be the result of the high percentage of BDNF Val-homozygous allele carriers in this population.

The present study emphasizes the interaction between BDNF polymorphism and PA as a set of life habits that is recognized as beneficial for brain health. We demonstrated that PA interacted with *BDNFVal66Met* on controlled inhibitory performance. Therefore, it is imperative to control for PA level to examine the putative impact of the *BDNFVal66Met* polymorphism on cognition in elderly populations.

Five main limitations may be noted. First, this study was cross-sectional. The interpretation of these results as a causal relationship between PA and cognition is limited by the study design; cross-sectional study do not allow establishing a causal relationship because better cognitive functioning may promote an individual to engage in PA. Future studies should use a randomized-controlled trial approach to determine whether BDNF *Val-*homozygous carriers benefit from exercise training programs. Second, the measure of PA was based on the self-report of participants. These factors induce the possibility of a biased reporting from the subjective perception of participants about their PA level. However, the HLAQ questionnaire and the NASA/JSC Physical Activity Scale are widely recognized and well-validated instruments. Third, some haplogroups may present protective or compensative effects to certain alterations in protein secretion that is influenced by a gene polymorphism. [@B58] demonstrated that the *Met* allele protected Asian-type populations from the deleterious effects of cognitive aging. It could be important to conduct replication of the present study and Thibeau's et al. ([@B57]) study in aging people from other ethnic group such as Asian-type population. Fourth, only one gene related to executive control was examined in the present study. However, executive control and the association between physical fitness and cognition are likely to be underpinned by many genes. Several genes have been identified in addition to BDNF: DRD4, DAT1, MAOA, COMT, APOE, each with a relatively small effect (for a review, [@B27]). It could be interesting to examine the synergistic and antagonistic actions of these different genes on cognition, and focus on those that share a common mechanism that may explain the causal link between exercise and cognition. However, these multi-polymorphisms studies require very large sample of participants.

The present report showed a significant interaction between PA and a *BDNF* gene polymorphism on controlled inhibitory performance. These data demonstrated that the association between PA and controlled inhibition was modulated by a *BDNF* polymorphism. Inactivity appeared more deleterious for Val-homozygous than *Met* carriers. This result improves our understanding of the neurophysiological mechanisms underlying the positive effect of PA on cognitive decline and provides brain BDNF as a convincing modulating candidate in this relationship.
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